See more : Fifth Third Bancorp (FITBO) Income Statement Analysis – Financial Results
Complete financial analysis of Invivyd, Inc. (IVVD) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Invivyd, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Locust Walk Acquisition Corp. (LWACU) Income Statement Analysis – Financial Results
- HighPeak Energy, Inc. (HPKEW) Income Statement Analysis – Financial Results
- ARYZTA AG (ARZTY) Income Statement Analysis – Financial Results
- Guangzhou Baiyun Electric Equipment Co., Ltd. (603861.SS) Income Statement Analysis – Financial Results
- LIGAND PHARMACEUTICAL INC (LGNZZ) Income Statement Analysis – Financial Results
Invivyd, Inc. (IVVD)
About Invivyd, Inc.
Adagio Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company's lead product candidate is the ADG20 (adintrevimab), a neutralizing antibody that is in Phase 3 clinical trials for the treatment and prevention of coronavirus disease. Adagio Therapeutics, Inc. has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies; and the Scripps Research Institute to perform research activities to identify vaccine candidates for the prevention, diagnosis or treatment of influenza or beta coronaviruses. The company was incorporated in 2020 and is based in Waltham, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 2.03M | 462.00K | 1.00K | 0.00 |
| Gross Profit | -2.03M | -462.00K | -1.00K | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 158.66M | 179.21M | 182.89M | 62.12M |
| General & Administrative | 0.00 | 47.04M | 36.52M | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 47.10M | 47.04M | 36.52M | 3.21M |
| Other Expenses | 0.00 | 6.71M | 118.00K | 0.00 |
| Operating Expenses | 205.76M | 226.26M | 219.41M | 65.33M |
| Cost & Expenses | 207.78M | 226.26M | 219.41M | 65.33M |
| Interest Income | 0.00 | 6.71M | 118.00K | 8.00K |
| Interest Expense | 0.00 | 43.08M | 0.00 | 0.00 |
| Depreciation & Amortization | 2.03M | 462.00K | 1.00K | 43.20M |
| EBITDA | -196.62M | -248.03M | -226.79M | -65.33M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -207.78M | -248.03M | -226.91M | -65.33M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 9.14M | 6.71M | -7.38M | 8.00K |
| Income Before Tax | -198.64M | -241.32M | -226.79M | -65.32M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -6.71M | 7.50M | -43.20K |
| Net Income | -198.64M | -234.60M | -234.29M | -65.32M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -1.81 | -2.17 | -2.11 | -0.59 |
| EPS Diluted | -1.81 | -2.17 | -2.11 | -0.59 |
| Weighted Avg Shares Out | 109.53M | 108.27M | 110.78M | 111.25M |
| Weighted Avg Shares Out (Dil) | 109.53M | 108.27M | 110.78M | 111.25M |
Adagio: A COVID-19 Play With Big Potential On Possible Treatment And Prevention
12 biotech stocks to consider buying now as prospects for the sector brighten this year
Top 5 IPOs of 2021
Why Shares of Adagio Therapeutics Soared 25.9% on Thursday
5 Top Biotech Stocks To Watch In January 2022
Adagio Therapeutics Stock (ADGI): Why The Price Went Up Today
Adagio Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference
Why Adagio Therapeutics Stock Dived by 13% Today
Adagio Therapeutics Stock (ADGI): Why The Price Surged Over 120% Today
ADGI Stock Alert: 4 Things to Know as Adagio Therapeutics Rockets 100%
Source: https://incomestatements.info
Category: Stock Reports